JK-1201I + Temozolomide for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Oct 2022: Trial started, NCT06595186
  2. 19 Sep 2024: Trial registered, NCT06595186

The trials

NCT06595186: JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

State
Under way
Phase
Phase 2
People
25 planned
Started
31 Oct 2022
Primary completion
16 Aug 2026
Arms
Dose Escalation Cohort, Dose Expansion Cohort
Results
None posted
  1. 31 Oct 2022: Trial started
  2. 19 Sep 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.